Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma
- Junjian Shen 1, Xingxing Wang 2, Keqin Yu 1, Kai Liu 1, Xiaolin Wang 3, Haitao Sun 4, Jianjun Zhou 5, Mengsu Zeng 1
- Junjian Shen 1, Xingxing Wang 2, Keqin Yu 1
- 1Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- 2, Department of Pathology, Zhongshan Hospital, Fudan University, PR China.
- 3, Department of Interventional Radiology, Zhongshan Hospital, Fudan university, PR China.
- 4Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. sht1720@163.com.
- 5Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, PR China.
- 0Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) shows distinct clinical features and poorer prognosis. MRI reveals larger tumor size and rim enhancement in KRAS-mutated PDAC, aiding in diagnosis.
Area Of Science
- Oncology
- Radiology
- Genetics
Background
- Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer mortality.
- KRAS mutations are common in PDAC and influence tumor behavior.
- Accurate identification of KRAS mutation status is crucial for treatment strategies.
Purpose Of The Study
- To identify magnetic resonance imaging (MRI) features associated with KRAS mutation status in PDAC.
- To explore the clinical implications of these MRI findings.
- To correlate imaging characteristics with clinicopathological features and prognosis.
Main Methods
- Retrospective analysis of 308 surgically confirmed PDAC patients with genetic testing for KRAS mutation status.
- Comparison of contrast-enhanced MRI features, clinicopathologic findings, and overall survival (OS) between KRAS-mutated and non-KRAS-mutated PDAC groups.
- Statistical analysis to determine associations between MRI features, clinicopathology, and KRAS status.
Main Results
- KRAS-mutated PDAC (n=258) showed higher rates of diabetes, peripheral nerve infiltration, and advanced pN stage compared to non-mutated PDAC (n=50).
- Patients with KRAS-mutated PDAC had a significantly worse 1-, 3-, and 5-year overall survival (OS) rate.
- Distinctive MRI features for KRAS-mutated PDAC included rim enhancement and larger tumor size.
Conclusions
- KRAS-mutated PDAC exhibits unique clinical and pathological characteristics.
- KRAS-mutated PDAC is associated with a poorer prognosis.
- MRI findings of rim enhancement and larger tumor size are indicative of KRAS-mutated PDAC.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.